drugset / Trial / NCT04702048

Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye

NCT04702048 ↗

Phase 4 Withdrawn University of Rochester
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to specifically assess the effect of intravitreal aflibercept injections on the health of cells and the flow of blood through the retinal blood vessels by using advanced technology called adaptive optics.

Timeline

Start
2021-02-01
Primary completion
2024-02-01
Completion
2024-02-01

Outcome

Outcome not reported

Stopped (Business): “sponsor withdrew funding”

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal

Indications